|
|
BGI Genomics
Products >> Natera and BGI Genomics Announce $50M Partnership to Commerciali
Build Your Online Product Catalogs?
| Product Name: |
Natera and BGI Genomics Announce $50M Partnership to Commerciali
|
| Supply Ability: |
|
| Related proudcts |
natera and bgi genom, |
| Specifications |
Natera and BGI Genomics Announce $50M Partnership to Commerciali |
| Price Term: |
|
| Port of loading: |
|
| Minimum Order |
|
| Unit Price: |
|
|
SAN CARLOS, Calif. and SHENZHEN, China, March 11, 2019 /PRNewswire/ ¡ª Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA genetic testing, and BGI Genomics Co., Ltd., (300676.SZ), the largest cell-free DNA clinical testing laboratory in China and one of the world¡¯s leading genomics co***nies, today announced a $50 million partnership to commercialize Natera¡¯s Signatera&©|8482; MRD test in China, and to develop reproductive health tests in select markets on BGI¡¯s sequencing instruments using the DNBseq&©|8482; NGS technology platform.
The Natera Signatera MRD and molecular monitoring test will be offered in China, first through specialty hospital networks and then more broadly, once Natera and BGI Genomics gain China¡¯s regulatory approval for use of the Signatera test on the DNBseq&©|8482; technology platform. DNBseq&©|8482; is the market name of BGI¡¯s proprietary sequencing technology, which supports its portfolio of next-generation sequencing platforms. BGI Genomics¡¯ genetic testing leadership position in China, where it performs over 1 million cell-free DNA tests annually,1 will accelerate Natera¡¯s entry into this large and growing oncology market.
Cancer is the leading cause of death in China with roughly 4.3 million new cancer cases and 2.8 million deaths reported annually.2 The molecular diagnostics market in China is a rapidly growing multi-billion-dollar market, driven largely by the rising incidence of cancer and infectious diseases.3
"Natera shares our core vision of improving human health by offering innovative BGI gene test solutions that allow for earlier and more effective diagnosis of disease," said Yin Ye, CEO at BGI Genomics. "Natera¡¯s decision to launch its Signatera test into China on BGI¡¯s DNBseq&©|8482; technology platform is a testament to both the quality and versatility of our technology. We look forward to working together with Natera for the general benefit of people worldwide and to expanding access to the DNBseq&©|8482; technology platform to other customers globally. |
| Company: |
BGI Genomics
|
| Contact: |
Tommy Ru |
| Address: |
beijing |
| Postcode: |
|
| Tel: |
17722567742 |
| Fax: |
|
| E-mail: |
|
|
|
|
Home
